Vcanbio Cell & Gene Engineering Corp Ltd (600645) - Net Assets

Latest as of September 2025: CN¥3.76 Billion CNY ≈ $550.45 Million USD

Based on the latest financial reports, Vcanbio Cell & Gene Engineering Corp Ltd (600645) has net assets worth CN¥3.76 Billion CNY (≈ $550.45 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.32 Billion ≈ $778.11 Million USD) and total liabilities (CN¥1.56 Billion ≈ $227.66 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Vcanbio Cell & Gene Engineering Corp Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥3.76 Billion
% of Total Assets 70.74%
Annual Growth Rate 12.55%
5-Year Change 4.47%
10-Year Change 117.57%
Growth Volatility 33.73

Vcanbio Cell & Gene Engineering Corp Ltd - Net Assets Trend (1992–2024)

This chart illustrates how Vcanbio Cell & Gene Engineering Corp Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Vcanbio Cell & Gene Engineering Corp Ltd total assets for the complete picture of this company's asset base.

Annual Net Assets for Vcanbio Cell & Gene Engineering Corp Ltd (1992–2024)

The table below shows the annual net assets of Vcanbio Cell & Gene Engineering Corp Ltd from 1992 to 2024. For live valuation and market cap data, see Vcanbio Cell & Gene Engineering Corp Ltd market cap and net worth.

Year Net Assets Change
2024-12-31 CN¥3.66 Billion
≈ $535.44 Million		 -3.67%
2023-12-31 CN¥3.80 Billion
≈ $555.86 Million		 +3.97%
2022-12-31 CN¥3.65 Billion
≈ $534.64 Million		 +3.42%
2021-12-31 CN¥3.53 Billion
≈ $516.95 Million		 +0.87%
2020-12-31 CN¥3.50 Billion
≈ $512.51 Million		 +1.20%
2019-12-31 CN¥3.46 Billion
≈ $506.41 Million		 +15.96%
2018-12-31 CN¥2.98 Billion
≈ $436.71 Million		 +82.60%
2017-12-31 CN¥1.63 Billion
≈ $239.17 Million		 -6.70%
2016-12-31 CN¥1.75 Billion
≈ $256.34 Million		 +4.16%
2015-12-31 CN¥1.68 Billion
≈ $246.10 Million		 +45.45%
2014-12-31 CN¥1.16 Billion
≈ $169.20 Million		 +75.18%
2013-12-31 CN¥660.07 Million
≈ $96.59 Million		 +134.45%
2012-12-31 CN¥281.54 Million
≈ $41.20 Million		 +4.72%
2011-12-31 CN¥268.85 Million
≈ $39.34 Million		 +10.13%
2010-12-31 CN¥244.13 Million
≈ $35.72 Million		 +2.05%
2009-12-31 CN¥239.23 Million
≈ $35.01 Million		 -6.66%
2008-12-31 CN¥256.31 Million
≈ $37.51 Million		 +38.23%
2007-12-31 CN¥185.42 Million
≈ $27.13 Million		 +0.75%
2006-12-31 CN¥184.04 Million
≈ $26.93 Million		 +11.57%
2005-12-31 CN¥164.95 Million
≈ $24.14 Million		 -46.78%
2004-12-31 CN¥309.95 Million
≈ $45.36 Million		 -15.09%
2003-12-31 CN¥365.02 Million
≈ $53.41 Million		 +2.01%
2002-12-31 CN¥357.83 Million
≈ $52.36 Million		 -13.58%
2001-12-31 CN¥414.06 Million
≈ $60.59 Million		 -4.58%
2000-12-31 CN¥433.95 Million
≈ $63.50 Million		 +4.79%
1999-12-31 CN¥414.12 Million
≈ $60.60 Million		 -0.56%
1998-12-31 CN¥416.47 Million
≈ $60.94 Million		 +45.11%
1997-12-31 CN¥287.01 Million
≈ $42.00 Million		 +14.71%
1996-12-31 CN¥250.20 Million
≈ $36.61 Million		 +20.11%
1995-12-31 CN¥208.30 Million
≈ $30.48 Million		 +21.74%
1994-12-31 CN¥171.11 Million
≈ $25.04 Million		 +24.64%
1993-12-31 CN¥137.28 Million
≈ $20.09 Million		 +64.94%
1992-12-31 CN¥83.23 Million
≈ $12.18 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Vcanbio Cell & Gene Engineering Corp Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 5220.5% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock CN¥467.95 Million 13.02%
Other Comprehensive Income CN¥172.39 Million 4.80%
Other Components CN¥3.17 Billion 88.23%
Total Equity CN¥3.60 Billion 100.00%

Vcanbio Cell & Gene Engineering Corp Ltd Competitors by Market Cap

The table below lists competitors of Vcanbio Cell & Gene Engineering Corp Ltd ranked by their market capitalization.

Company Market Cap
IReader Technology Co Ltd
SHG:603533
 $1.70 Billion
Monarch Casino & Resort Inc
NASDAQ:MCRI
 $1.70 Billion
SEPLAT ENERGY (DI) NA-50
F:134
 $1.70 Billion
HJ ShipBuilding & Construction Co Ltd
KO:097230
 $1.70 Billion
Bolsas y Mercados Argentinos SA
BA:BYMA
 $1.70 Billion
Kfin Technologies Limited
NSE:KFINTECH
 $1.70 Billion
Farglory Land Development Co Ltd
TW:5522
 $1.70 Billion
Xintec
TWO:3374
 $1.70 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Vcanbio Cell & Gene Engineering Corp Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 3,684,062,269 to 3,595,087,564, a change of -88,974,705 (-2.4%).
  • Net income of 100,352,117 contributed positively to equity growth.
  • Dividend payments of 591,243 reduced retained earnings.
  • Share repurchases of 200,025,328 reduced equity.
  • Other comprehensive income increased equity by 14,227,346.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥100.35 Million +2.79%
Dividends Paid CN¥591.24K -0.02%
Share Repurchases CN¥200.03 Million -5.56%
Other Comprehensive Income CN¥14.23 Million +0.4%
Other Changes CN¥-2.94 Million -0.08%
Total Change CN¥- -2.42%

Book Value vs Market Value Analysis

This analysis compares Vcanbio Cell & Gene Engineering Corp Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.16x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 45.35x to 3.16x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1993-12-31 CN¥0.55 CN¥24.87 x
1994-12-31 CN¥0.68 CN¥24.87 x
1995-12-31 CN¥0.83 CN¥24.87 x
1996-12-31 CN¥1.00 CN¥24.87 x
1997-12-31 CN¥1.10 CN¥24.87 x
1998-12-31 CN¥1.62 CN¥24.87 x
1999-12-31 CN¥1.58 CN¥24.87 x
2000-12-31 CN¥1.67 CN¥24.87 x
2001-12-31 CN¥1.44 CN¥24.87 x
2002-12-31 CN¥1.21 CN¥24.87 x
2003-12-31 CN¥1.21 CN¥24.87 x
2004-12-31 CN¥0.90 CN¥24.87 x
2005-12-31 CN¥0.26 CN¥24.87 x
2006-12-31 CN¥0.30 CN¥24.87 x
2007-12-31 CN¥0.27 CN¥24.87 x
2008-12-31 CN¥0.39 CN¥24.87 x
2009-12-31 CN¥0.42 CN¥24.87 x
2010-12-31 CN¥0.41 CN¥24.87 x
2011-12-31 CN¥0.47 CN¥24.87 x
2012-12-31 CN¥0.42 CN¥24.87 x
2013-12-31 CN¥1.39 CN¥24.87 x
2014-12-31 CN¥2.91 CN¥24.87 x
2015-12-31 CN¥4.03 CN¥24.87 x
2016-12-31 CN¥4.19 CN¥24.87 x
2017-12-31 CN¥4.37 CN¥24.87 x
2018-12-31 CN¥7.02 CN¥24.87 x
2019-12-31 CN¥7.42 CN¥24.87 x
2020-12-31 CN¥7.30 CN¥24.87 x
2021-12-31 CN¥7.40 CN¥24.87 x
2022-12-31 CN¥7.60 CN¥24.87 x
2023-12-31 CN¥7.96 CN¥24.87 x
2024-12-31 CN¥7.88 CN¥24.87 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Vcanbio Cell & Gene Engineering Corp Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 2.79%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 6.33%
  • • Asset Turnover: 0.30x
  • • Equity Multiplier: 1.46x
  • Recent ROE (2.79%) is below the historical average (4.90%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1993 14.67% 16.50% 0.67x 1.33x CN¥6.42 Million
1994 18.46% 17.84% 0.63x 1.65x CN¥14.38 Million
1995 10.16% 14.43% 0.37x 1.90x CN¥326.79K
1996 10.24% 10.05% 0.59x 1.72x CN¥593.19K
1997 10.54% 9.76% 0.49x 2.19x CN¥1.50 Million
1998 4.80% 10.44% 0.28x 1.66x CN¥-21.03 Million
1999 5.01% 19.89% 0.15x 1.66x CN¥-19.78 Million
2000 4.33% 9.01% 0.30x 1.62x CN¥-23.71 Million
2001 0.70% 0.85% 0.38x 2.17x CN¥-33.53 Million
2002 -20.95% -20.34% 0.55x 1.88x CN¥-93.54 Million
2003 1.04% 0.97% 0.51x 2.11x CN¥-27.05 Million
2004 -34.82% -27.85% 0.50x 2.48x CN¥-100.82 Million
2005 10.50% 1.90% 0.73x 7.60x CN¥317.96K
2006 10.20% 1.91% 0.70x 7.59x CN¥155.10K
2007 13.68% 3.03% 0.67x 6.78x CN¥3.19 Million
2008 31.05% 13.57% 0.44x 5.18x CN¥26.51 Million
2009 1.66% 0.69% 0.44x 5.47x CN¥-10.68 Million
2010 6.32% 3.28% 0.33x 5.82x CN¥-4.87 Million
2011 15.02% 10.07% 0.27x 5.43x CN¥7.83 Million
2012 9.49% 4.63% 0.24x 8.42x CN¥-754.66K
2013 1.44% 2.00% 0.24x 2.96x CN¥-42.93 Million
2014 3.43% 7.44% 0.20x 2.34x CN¥-67.78 Million
2015 13.41% 29.39% 0.25x 1.81x CN¥53.01 Million
2016 2.38% 4.52% 0.28x 1.89x CN¥-120.92 Million
2017 0.69% 0.78% 0.44x 1.99x CN¥-140.54 Million
2018 2.14% 4.49% 0.30x 1.60x CN¥-218.00 Million
2019 1.48% 3.58% 0.28x 1.46x CN¥-285.68 Million
2020 -3.71% -9.62% 0.27x 1.43x CN¥-468.37 Million
2021 4.48% 10.12% 0.31x 1.45x CN¥-191.03 Million
2022 3.18% 7.27% 0.29x 1.49x CN¥-242.59 Million
2023 2.89% 6.70% 0.29x 1.47x CN¥-261.95 Million
2024 2.79% 6.33% 0.30x 1.46x CN¥-259.16 Million

Industry Comparison

This section compares Vcanbio Cell & Gene Engineering Corp Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $6,387,359,426
  • Average return on equity (ROE) among peers: 2.03%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Vcanbio Cell & Gene Engineering Corp Ltd (600645) CN¥3.76 Billion 14.67% 0.41x $1.70 Billion
Shenzhen CAU Technology Co Ltd (000004) $948.24 Million -53.63% 0.17x $53.47 Million
Pacific Shuanglin Bio pharmacy Co Ltd (000403) $7.92 Billion 9.41% 0.17x $1.63 Billion
Nanhua Bio Medicine Co Ltd (000504) $304.67 Million -9.25% 1.53x $444.78 Million
Jiangsu Sihuan Bioengineering Co Ltd (000518) $1.06 Billion 8.06% 0.08x $444.44 Million
Chengzhi Shareholding Co Ltd (000990) $15.52 Billion 0.71% 0.30x $2.24 Billion
Hualan Biological EngineeringInc (002007) $6.88 Billion 18.64% 0.10x $3.87 Billion
Da An Gene Co Ltd of Sun Yat-Sen University (002030) $428.60 Million 11.05% 0.37x $1.25 Billion
Shanghai RAAS Blood Products Co Ltd Class A (002252) $29.65 Billion 6.00% 0.08x $5.41 Billion
Baolingbao Biology Co Ltd (002286) $703.11 Million 6.09% 0.47x $568.58 Million
Tibet Cheezheng Tibetan Medicine Co Ltd (002287) $456.61 Million 23.20% 0.29x $1.91 Billion

About Vcanbio Cell & Gene Engineering Corp Ltd

SHG:600645 China Biotechnology
Market Cap
$1.70 Billion
CN¥11.64 Billion CNY
Market Cap Rank
#6906 Global
#1604 in China
Share Price
CN¥24.87
Change (1 day)
-3.87%
52-Week Range
CN¥21.44 - CN¥32.94
All Time High
CN¥68.93
Categories
Companies in China Biotechnology
About

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People's Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells, and dental ste… Read more